FFG
ANIP icon

Fortem Financial Group’s ANI Pharmaceuticals ANIP Stock Holding History

Fortem Financial Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-805
Closed -$23K – 179
2020
Q4 		$23K Buy
+805
New +$23.1K 0.01% 302

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Fortem Financial Group's ANIP Position: Q1 2021 in Review

Fortem Financial Group sold out of ANI Pharmaceuticals (ANIP) in Q1 2021, closing a stake of 805 shares — an estimated $23K sold.

Fortem Financial Group first reported a position in ANIP in Q4 2020 and held it in 1 quarter. The position peaked at $23K in Q4 2020. 106 funds tracked by Wall St. Rank hold ANIP as of Q1 2021.

  • Fortem Financial Group reported no remaining ANI Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Fortem Financial Group sold 805 ANI Pharmaceuticals shares in Q1 2021, an estimated $23K.
  • Fortem Financial Group first reported a position in ANI Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Fortem Financial Group's ANI Pharmaceuticals position peaked at $23K in Q4 2020.
  • 106 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2021.

Based on Fortem Financial Group's 13F filing for Q1 2021, filed 20 Apr 2021.